Ravi Shankar Keshari

Ravi Shankar Keshari

Auto-generated profile, based on publicly available information

Ravi Shankar Keshari

Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2015 in Blood
Verified
Journal Article
Open access
PDF file
HCHala Chaaban
Hala Chaaban
RKRavi S. Keshari
Ravi S. Keshari
RSRobert Silasi
Robert Silasi
NPNarcis I. Popescu
Narcis I. Popescu
PMPadmaja Mehta-D’sOuza
Padmaja Mehta-D’sOuza
FLFlorea Lupu
Florea Lupu
Key Points: IAIP and its anionic carbohydrate moieties bind and inhibit the damaging effects of histones both in vitro and in vivo. Cell-surface–associated negatively charged glycocalyx and matrix-associated glycosminoglycans protect against histone-induced cytotoxicity.

26 February 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
RSRobert Silasi
Robert Silasi
RKRavi Shankar Keshari
Ravi Shankar Keshari
CLCristina Lupu
Cristina Lupu
WRWalter Janse Van Rensburg
Walter Janse Van Rensburg
HCHala Chaaban
Hala Chaaban
FLFlorea Lupu
Florea Lupu
Staphylococcus aureus infections can produce systemic bacteremia and inflammation in humans, which may progress to severe sepsis or septic shock, even with appropriate antibiotic treatment. Sepsis may be associated with disseminated intravascular coagulation and consumptive coagulopathy. In some types of mouse infection models, the plasma coagulation protein factor XI (FXI) contributes to the pathogenesis of sepsis. We hypothesize that FXI also contributes to the pathogenesis of sepsis in primates, and that pharmacological interference with FXI will alter the outcome of Staphylococcus aureus–induced lethality in a baboon model. Pretreatment of baboons with the anti-FXI antibody 3G3, a humanized variant of the murine monoclonal 14E11 that blocks FXI activation by FXIIa, substantially reduced the activation of coagulation, as reflected by clotting times and plasma complexes of coagulation proteases (FXIIa, FXIa, FIXa, FXa, FVIIa, and thrombin) with serpins (antithrombin or C1 inhibitor) following infusion of heat-inactivated S aureus. 3G3 treatment reduced fibrinogen and platelet consumption, fibrin deposition in tissues, neutrophil activation and accumulation in tissues, cytokine production, kininogen cleavage, cell death, and complement activation. Overall, 3G3 infusion protected the structure and function of multiple vital organs, including lung, heart, liver, and kidney. All treated animals reached the end point survival (7 days), whereas all nontreated animals developed terminal organ failure within 28 hours. We conclude that FXI plays a role in the pathogenesis of S aureus–induced disseminated intravascular coagulation and lethality in baboons. The results provide proof of concept for future therapeutic interventions that may prevent sepsis-induced organ failure and save lives in certain forms of sepsis.

24 October 2024 in Blood
Verified
Journal Article
Closed access
CPCristina Puy
Cristina Puy
SMSamantha A. Moellmer
Samantha A. Moellmer
JPJiaqing Pang
Jiaqing Pang
HVHelen H. Vu
Helen H. Vu
AMAlexander R. Melrose
Alexander R. Melrose
OMOwen J. T. McCarty
Owen J. T. McCarty
Loss of endothelial barrier function contributes to the pathophysiology of many inflammatory diseases. Coagulation factor XI (FXI) plays a regulatory role in inflammation. Although activation of FXI increases vascular permeability in vivo, the mechanism by which FXI or its activated form FXIa disrupts endothelial barrier function is unknown. We investigated the role of FXIa in human umbilical vein endothelial cell (HUVEC) or human aortic endothelial cell (HAEC) permeability. The expression patterns of vascular endothelial (VE)-cadherin and other proteins of interest were examined by western blot or immunofluorescence. Endothelial cell permeability was analyzed by Transwell assay. We demonstrate that FXIa increases endothelial cell permeability by inducing cleavage of the VE-cadherin extracellular domain, releasing a soluble fragment. The activation of a disintegrin and metalloproteinase 10 (ADAM10) mediates the FXIa-dependent cleavage of VE-cadherin, because adding an ADAM10 inhibitor prevented the cleavage of VE-cadherin induced by FXIa. The binding of FXIa with plasminogen activator inhibitor 1 and very low–density lipoprotein receptor on HUVEC or HAEC surfaces activates vascular endothelial growth receptor factor 2 (VEGFR2). The activation of VEGFR2 triggers the mitogen-activated protein kinase (MAPK) signaling pathway and promotes the expression of active ADAM10 on the cell surface. In a pilot experiment using an established baboon model of sepsis, the inhibition of FXI activation significantly decreased the levels of soluble VE-cadherin to preserve barrier function. This study reveals a novel pathway by which FXIa regulates vascular permeability. The effect of FXIa on barrier function may be another way by which FXIa contributes to the development of inflammatory diseases.

8 June 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
HCHala Chaaban
Hala Chaaban
KBKathryn Burge
Kathryn Burge
JEJeffrey Eckert
Jeffrey Eckert
RKRavi S. Keshari
Ravi S. Keshari
RSRobert Silasi
Robert Silasi
FLFlorea Lupu
Florea Lupu
Necrotizing enterocolitis (NEC) is a devastating gastrointestinal disease affecting primarily premature infants. The disease is characterized by intestinal inflammation and leucocyte infiltration, often progressing to necrosis, perforation, systemic inflammatory response and death. Neutrophil extracellular traps (NETs), denoting nuclear DNA, histone and antimicrobial protein release, have been suggested to play a role in NEC. This study aimed to determine the role of NETs in NEC and explore the effect of chloramidine, a NET inhibitor, on a murine NEC‐like intestinal injury model. Blood and intestinal tissues were collected from infants diagnosed with ≥ Stage II NEC, and levels of nucleosomes and NETs, respectively, were compared with those of case‐matched controls. In mice, NEC was induced with dithizone/Klebsiella, and mice in the treatment group received 40 mg/kg chloramidine. Bacterial load, intestinal histology, plasma myeloperoxidase and cytokine levels, and immunofluorescent staining were compared with controls. Nucleosomes were significantly elevated in both human and mouse NEC plasma, whereas NET staining was only present in NEC tissue in both species. Chloramidine treatment increased systemic inflammation, bacterial load, organ injury and mortality in murine NEC. Taken together, our findings suggest that NETs are critical in the innate immune defence during NEC in preventing systemic bacteraemia.

23 August 2018 in Blood
Verified
Journal Article
Open access
PDF file
NPNarcis I. Popescu
Narcis I. Popescu
RSRobert Silasi
Robert Silasi
RKRavi S. Keshari
Ravi S. Keshari
AGAlanson Girton
Alanson Girton
TBTarea Burgett
Tarea Burgett
KCK. Mark Coggeshall
K. Mark Coggeshall
Key Points: PGN infusion mimics the systemic inflammation and coagulopathy observed in late-stage B anthracis challenge. PGN directly activates the extrinsic coagulation and promotes contact pathway amplification in nonhuman primates.

14 December 2017 in Blood
Verified
Journal Article
Open access
PDF file
RKRavi S. Keshari
Ravi S. Keshari
RSRobert Silasi
Robert Silasi
CLCristina Lupu
Cristina Lupu
FTFletcher B. Taylor
Fletcher B. Taylor
FLFlorea Lupu
Florea Lupu
Sepsis concurrently activates both coagulation and complement systems. Although complement activation by bacteria is well documented, work in mice and in vitro suggests that coagulation proteases can directly cleave complement proteins. We aimed to determine whether generation of coagulation proteases in vivo can activate the complement cascade in 2 highly coagulopathic models. We compared temporal changes in activation biomarkers of coagulation (thrombin-antithrombin [TAT]), fibrinolysis (plasmin-antiplasmin [PAP]), and complement (C3b, C5a, C5b-9) in baboons infused with factor Xa (FXa) and phospholipids (FXa/phosphatidylcholine-phosphatidylserine [PCPS]) vs LD100 Escherichia coli. We found that, albeit with different timing, both FXa/PCPS and E coli infusion led to robust thrombin and plasmin generation. Conversely, only E coli challenge activated the complement system, reaching a maximum at 2 hours postchallenge during the peaks of lipopolysaccharide and bacteremia but not of TAT and PAP. Despite inducing a strong burst of thrombin and plasmin, FXa/PCPS infusion did not produce measurable levels of complement activation in vivo. Similarly, ex vivo incubation of baboon serum with thrombin, plasmin, or FXa did not show noticeable complement cleavage unless supraphysiologic amounts of enzymes were used. Our results suggest that in vivo–generated thrombin and plasmin do not directly activate the complement in nonhuman primates. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points In vivo–generated thrombin and plasmin do not contribute to complement activation in nonhuman primates. Bacteria and lipopolysaccharide are the main drivers of in vivo complement activation in E coli sepsis in baboons.